Compare Nexgen Energy Ltd. Common Shares (NXE) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nexgen Energy Ltd. Common Shares vs Summit Therapeutics Inc — how do they compare? Nexgen Energy Ltd. Common Shares trades at $8.75 (market cap $5.80B), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 2.4× Nexgen Energy Ltd. Common Shares's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, Nexgen Energy Ltd. Common Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nexgen Energy Ltd. Common Shares for 1 Days and Summit Therapeutics Inc for 16 Days on average.
| NXE | SMMT | |
|---|---|---|
Market Cap | $5.80B | $13.71B |
Volume | 6,795,738 | 6,173,057 |
Sector | Energy | Health |
52-Week High | $13.92 | $26.38 |
52-Week Low | $7.56 | $12.43 |
Typical Hold Time | 1 Days | 16 Days |
Enterprise Value | $5.55B | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.
The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nexgen Energy Ltd. Common Shares
NexGen Energy develops uranium projects in Canada. Its main asset is the Rook I Project in Saskatchewan, which includes the Arrow uranium deposit.
Read more on NXE →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
